Sign in
Taking people in South KoreaPhase 4

Cerebrolysin for long-lasting disorders of consciousness after bleeding stroke

Tests cerebrolysin against a saline control in people with consciousness disorders after hemorrhagic stroke.

Key facts

Who runs it
Konkuk University Medical Center
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness
Status
Recruiting
Phase
Phase 4
People taking part
12 people, planned
Started
1 Jun 2023
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cerebrolysin
  • Control
Record updated
11 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a hemorrhagic stroke who have been in a disorder of consciousness (vegetative or minimally conscious state) for more than 4 weeks.

Age
19 to 80 years (the registry also lists a maximum age of 120 years)
Sex
All sexes can join.
Disease stage
Hemorrhagic stroke confirmed by CT or MRI, with a disorder of consciousness lasting more than 4 weeks. The person is in a vegetative state or minimally conscious state (Coma Recovery Scale-revised).
Earlier treatment
Cannot have long-term treatment with medicines that may affect consciousness, such as antidepressants, antipsychotic drugs, nootropic drugs and vasodilators.

Main reasons for not taking part

  • Epileptiform discharges confirmed on EEG
  • Brain parenchymal defects
  • Advanced liver, kidney, heart or lung disease
  • Alcohol or drug abuse or dependence within the last 2 years
  • Contraindications to cerebrolysin, or taking part in another therapeutic study

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients with hemorrhagic stroke confirmed by CT or MRI
  • Patients who have been in disorders of consciousness for more than 4 weeks after the onset of hemorrhagic stroke
  • Patients in a vegetative state or minimally conscious state (Coma Recovery Scale -revised: CRS-R assessment)
  • Age: 19 to 80 years of age
  • Patients who have voluntarily given written informed consent to participate in the study by themselves or their legal representative

Who cannot take part

  • Chronic treatment with medications that may affect consciousness, such as antidepressants, antipsychotic drugs, nootropic drugs, and vasodilators
  • Alcohol or drug abuse or dependence within the last 2 years (DSM-V criteria)
  • Administration of a contraindicated drug is essential for medical purposes
  • Contraindications to the study drug (cerebrolysin)
  • Patients with advanced liver, kidney, cardiac, or pulmonary disease
  • History of serious illness within the last two years (cancer, hematologic, renal, hepatic, or coronary artery disease, psychiatric illness, diabetes, myocardial infarction, epilepsy), no evidence of secondary damage to major organs, and well-controlled diabetes or hypertension
  • Significant systemic disease or unstable medical condition that may compromise compliance with the study protocol
  • Patients with confirmed epileptiform discharges on EEG
  • Patients with brain parenchymal defects
  • Participation in another therapeutic study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 19 and 120 years old?

Where in South Korea

  • Konkuk University Medical Center Research Coordinating CenterSeoul, South KoreaContact: Mi Soo Jang, Ph.D.Taking people

About the trial

What the trial wants to find out

Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke.

Read full original descriptionShow less

Participants: patients with prolonged disorders of consciousness due to severe traumatic brain injury

Intervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously or 100 ml normal saline, days 4-17, once/day, IV

Comparison: cerebrolysin group versus control group

Outcome: Coma Recovery Scale-revised, FDG-PET signal

The 2 groups in the trial

  • CerebrolysinTreatment being tested

    30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously

  • ControlPlacebo, for comparison

    100 ml normal saline, days 4-17, once/day, IV

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness in Patients With Hemorrhagic Stroke: A Pilot Study
Plain-language title
Cerebrolysin for long-lasting disorders of consciousness after bleeding strokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04427241, who can take part
Record updated
11 May 2026